Women and lung cancer: researchers look for the link between the sexes. Female cancer patients search for large-scale clinical trials

According to a recent survey on health concerns, women more fear of breast cancer. Despite the concerns expressed in the survey, conducted by the company for media women health research in 2005, lung cancer is actually cancer killer of women. Lung cancer is the lives of approximately 68,000 women each year.

While smoking is the main risk factor for lung cancer, there is increasing evidence that points to the differences between the sexes in the risk of developing lung cancer and the implications for the treatment of the disease in men and women.

For example, while the number of men diagnosed with lung cancer, the number of women has increased 60% since 1990. In addition, women who are non-smoking are 2.5 times more likely to develop lung cancer men who are non-smoking.

Scientific evidence underscores the estrogen as a difference between how does lung cancer in men against women. This difference biological undertook to have important implications for the treatment of lung cancer.

Create estrogen in women can influence the growth of lung cancer causing the synthesis of tumour-promoting proteins. Since women have higher levels of estrogen than men and young women have higher levels of estrogen of older women, this may be partly responsible for their increased risk for cell lung cancer (NSCLC) nonsmall.

The development of therapies that are favourably influenced by estrogen is able to provide a therapeutic approach, directed by genre, to treat disease.

Researchers are now studying a new approach to fighting lung cancer in women, which is based on a chemotherapy agent requesting the presence of estrogen in women and their effect on the metabolism of proteins in cancer cells. Cell Therapeutics, Inc. (CTI) initially developed XYOTAX (paclitaxel poliglumex) as a drug of lung cancer, for all patients, regardless of sex. Retrospective Analysis of two phase III clinical trials found that drugs compared to standard chemotherapy treatments was a significant survival advantage in women, while the equivalent survival in men.

New clinical trials now, cell Therapeutics overlooking another clinical study exclusively on women to see if the theory is true in most populous of women. The process, known as pioneer, is the first approval process for lung cancer directed exclusively to women and is expected to sign for 600 patients with advanced lung cancer.